Table 1.
P53-Induced Target Genes Most Significantly Upregulated in WT TP53 Cancers
| Gene | # Cancers | Significance of Upregulation in 2 WT TP53 vs 0 WT TP53 Tumors (P values) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| CRC | BRCA | UCEC | GBM | OVCA | BLCA | LUAD | LAML | STAD | LGG | ||
| RPS27L | 10/10 | 2E-04 | 3E-29 | 3E-19 | 6E-10 | 1E-04 | 1E-02 | 3E-10 | 1E-06 | 2E-10 | 3E-04 |
| TNFRSF10C | 9/10 | 3E-03 | 1E-32 | 7E-12 | 1E-03 | 8E-03 | 5E-04 | 1E-11 | - | 2E-03 | 7E-03 |
| CDKN1A (p21) | 10/10 | 1E-06 | 5E-09 | 8E-12 | 1E-04 | 4E-02 | 1E-02 | 1E-04 | 1E-07 | 5E-02 | 7E-03 |
| ZMAT3 | 10/10 | 8E-05 | 9E-04 | 1E-03 | 9E-03 | 1E-03 | 3E-02 | 2E-03 | 1E-06 | 1E-08 | 3E-10 |
| EDA2R | 9/10 | 2E-03 | - | 7E-15 | 3E-03 | 5E-04 | 3E-02 | 5E-12 | 1E-18 | 4E-03 | 5E-19 |
| DDB2 | 8/10 | 1E-09 | 9E-16 | 2E-13 | 6E-07 | - | 2E-02 | 3E-04 | 5E-05 | 2E-09 | - |
| PHLDA3 | 8/10 | 3E-11 | 6E-11 | 5E-04 | 5E-07 | 2E-02 | - | - | 4E-15 | 1E-02 | 2E-10 |
| SPATA18 | 7/9* | 4E-08 | 9E-14 | 1E-13 | - | * | 1E-04 | 3E-06 | 5E-04 | 2E-05 | - |
| FDXR | 9/10 | 6E-08 | 4E-07 | 2E-04 | 5E-08 | - | 3E-02 | 2E-02 | 6E-05 | 2E-05 | 9E-15 |
| MDM2 | 8/10 | 4E-05 | 2E-04 | 1E-13 | 1E-07 | 3E-02 | - | 1E-02 | 1E-07 | 2E-05 | - |
| TNFRSF10B | 9/10 | 2E-04 | 1E-03 | 5E-03 | 1E-04 | - | 2E-03 | 2E-05 | 2E-03 | 3E-03 | 3E-12 |
| AEN | 7/10 | 8E-05 | - | 7E-12 | 2E-07 | - | 3E-02 | 6E-05 | - | 2E-02 | 3E-12 |
*
SPATA18 not present in OVCA gene expression platform
CRC - colorectal carcinomas; BRCA - breast carcinomas; UCEC - uterine corpus endometrioid carcinoma; GBM – glioblastoma multiforme; OVCA - ovarian serous cystadenocarcinoma; BLCA – bladder carcinoma; LUAD: lung adenocarcinoma; LAML: acute myeloid leukemia; STAD: stomach adenocarcinoma; LGG: low grade glioma.